Carisma Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview

Carisma Therapeutics

04/08/2023 18:18

* Carisma Therapeutics Inc  CARM.OQ   CARM.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 7
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
revenue of $1.067 million, according to the mean estimate from 3
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Carisma
Therapeutics Inc
is for a loss of 60 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Carisma
Therapeutics Inc is $10​, above​ its last closing price
of $5.43. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.89       -0.89      -1.93     Missed  -116.9
 Dec. 31 2023  -2.20       -2.20      -0.80     Beat    63.6
 Sep. 30 2022  -1.60       -1.60      2.00      Beat    225​
 Jun. 30 2022  -2.60       -2.60      -3.20     Missed  -23.1
 ​​Mar.        -1.97       -2.00      0.00      Beat    100
 31 2022                                                
 Dec. 31 2021  -1.65       -1.47      0.80      Beat    154.5​
 Sep. 30 2021  -1.60       -1.40      7.20      Beat    614.3
 Jun. 30 2021  -1.29       -1.27      -3.00     Missed  -136.9
 This summary was machine generated August 4 at 17:18 GMT.  All
figures in US dollars  unless otherwise stated